Lutetium (177Lu) Vipivotide Tetraxetan | 177Lu-PSMA-617 | Pluvicto® is developed by Endocyte (Now part of Novartis) which uses drug conjugation technology to develop targeted therapies with companion imaging agents, including 177Lu-PSMA-617, a first-in-class investigational radioligand therapy...
In both trials, [177Lu]Lu-PSMA-617 had a good safety profile, with common adverse events being fatigue, nausea, dry mouth, marrow suppression and diarrhea. Given its efficacy and favorable safety even in heavily pre-treated patients, [177Lu]Lu-PSMA-617 provides hope to mCRPC patients and ...
Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.N Engl J Med.2021;385(12):1091-1103. doi:10.1056/NEJMoa21073227.Data on file. PLUVICTO NPS Numbers. Novartis Pharmaceuticals Corp; 2025....
(formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic)1. ...
EAST HANOVER, N.J.,March 23, 2022-- Novartis announced today that the US Food and Drug Administration (FDA) approvedPluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type o...
PSMA-617 LU-177VIPIVOTIDE TETRAXETAN LU-177VIPIVOTIDE TETRAXETAN LUTETIUM LU-177 CAS登记号 1703749-62-5 物质唯一标识(Unique Ingredient Identifier) G6UF363ECX 分子式 C49H68N9O16.Lu 国际化合物标识(International Chemical Identifier,InChI) RSTDSVVLNYFDHY-BGOLSCJMSA-K...
IP26-40LUTETIUM-177 PSMA RADIOLIGAND THERAPY IN TAXAN-NAIVE FIRST- AND SECOND-LINE METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FIRST-LINE ARPI THERAPY doi:10.1097/01.JU.0001110200.18879.65.40Wolters KluwerThe Journal of UrologyMike WenzelBenedikt HoehCarolin SiechFlorestan KollDaniel GroenerThomas...
81#Background:In March 2022, the US Food and Drug Administration approved177Lu-PSMA-617 for the treatment of patients with prostate-specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition (ARPI) ...
学习下核药(Pluvicto) 核药由载体(小分子、多肽、大分子等)、连接子和载体组成,更换螯合的核素可发挥不同作用,比如鳌合Ga-68(γ辐射)可肿瘤诊断,鳌合Lu-177(β辐射)可肿瘤治疗。 Pluvicto(lutetium Lu 177 vipivotide tetraxetan)结构式如下: Vipivotide tetraxetan (PSMA-617)可以结合到PSMA上,PSMA在80%以...
PLUVICTO® lutetium Lu 177 vipivotide tetraxetan 是一款靶向肿瘤细胞表面PSMA(前列腺特异性膜抗原),进而释放放射性镥177(Lutetium-177)杀死肿瘤细胞的RDC核药。 药物由诺华公司开发,2022年获FDA批准上市,用于治疗去势抵抗型前列腺癌(mCRPC)成人患者。 药物国内尚未上市,根据英文名我暂称它为镥鲁177肽(音译无出处...